Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer. KRAS mutations are one of the most frequently observed mutations in human cancers, making them a crucial target for precision oncology therapy.
MK-1084 is an investigational, oral covalent inhibitor of KRAS G12C, that is found in about 14% of people with non-small cell lung cancer. MK-1084 is currently under Phase 1 evaluation as monotherapy and as combined therapies in patients with KRAS G12C mutant advanced solid tumors.
Recherche 
+86 21 5895 0110 
